IL-10 promoter gene polymorphisms and sustained response to combination therapy in Taiwanese chronic hepatitis C patients
Journal
Digestive and Liver Disease
Journal Volume
41
Journal Issue
6
Pages
424-430
Date Issued
2009
Author(s)
Abstract
Background and aims: Host genetic factors may affect clinical outcomes of hepatitis C virus (HCV) infection; however, the possible mechanisms remain largely unknown. The role of immunopathogenesis in chronic hepatitis C leads to extensive exploration of host immunity including inflammatory cytokines. Methods: We examined interleukin 10 (IL-10) promoter gene polymorphisms at positions -1082, -819, and -592 relative to transcription start site and studied their association with response to 24 weeks of pegylated interferon plus ribavirin treatment in 143 chronic hepatitis C patients, of whom 97 (67.8%) achieved a sustained virologic response (SVR). In addition, 134 healthy adults were used as controls. Results: Of chronic hepatitis C patients, 111 (77.6%) were genotype 1 infection, 32 (22.4%) were genotype 2 infection. Patients with sustained virologic response were younger and had higher pretreatment ALT levels than those without. No statistical difference was found between chronic hepatitis C patients who achieved SVR or not in terms of gender, HCV genotype, pretreatment HCV RNA levels, and severity of liver disease. The serum IL-10 levels were comparable between healthy controls and chronic hepatitis C patients as well as between HCV patients with and without SVR. The distribution of IL-10 promoter gene polymorphisms at positions -1082, -819, and -592 relative to transcription start site was comparable between HCV patients and healthy controls as well as HCV patients with and without SVR. A high frequency of ATA haplotype of common IL-10 promoter gene SNPs was found in both chronic hepatitis C patients (70.3%) and healthy controls (69.8%). However, ATA haplotype was not associated with SVR in chronic hepatitis C patients. Conclusions: Our data fail to demonstrate the influence of IL-10 promoter gene polymorphisms on the response to combination therapy in Taiwanese chronic hepatitis C patients. The impact of genetic variations in IL-10 haplotype on the response to anti-HCV treatment among different ethnic populations deserves further examination. ? 2008 Editrice Gastroenterologica Italiana S.r.l.
SDGs
Other Subjects
interleukin 10; peginterferon alpha2a; peginterferon alpha2b; ribavirin; virus RNA; adult; age distribution; article; controlled study; disease severity; DNA polymorphism; drug response; female; gene frequency; genetic association; genetic variability; genotype; haplotype; hepatitis C; Hepatitis C virus; human; major clinical study; male; priority journal; sex difference; single nucleotide polymorphism; Taiwan; transcription initiation site; treatment duration; Adult; Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon Alfa-2a; Interferon Alfa-2b; Interleukin-10; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Ribavirin; Taiwan; Treatment Outcome; Young Adult
Type
journal article